Literature DB >> 31763286

Ivermectin: A Novel Method of Treatment of Nasal and Nasopharyngeal Myiasis.

Abu Sayeed1, Aftab Ahmed1, S C Sharma1, S A Hasan1.   

Abstract

To evaluate the efficacy of oral Ivermectin, in patients suffering from nasal and nasopharyngeal myiasis. This was a prospective study, comprising 80 patients of nasal and nasopharyngeal myiasis. Patients underwent clinical examination and nasal endoscopy at the time of presentation and findings were recorded. The patients were randomly divided in two groups. In group-I the patients underwent manual extraction of the maggots after instillation of chloroform and turpentine oil mixture, whereas the group-II patients underwent manual extraction with administration of two doses (24 h apart) of oral Ivermectin (6 mg each). The patients were instructed to record the time when they noticed shedding of maggots, and evaluated for the clearance of maggots by endoscopy after 24, 48 h and 7 days after the initial examination. The mean maggot shedding time (by t test) in Group-I was 41.23 ± 4.23 h and in Group-II was 24.60 ± 3.15 h. The difference being highly significant statistically, (p = 0.0001). The endoscopic clearance of maggots (by Chi square test) between the two group of patients was also statistically significant at 24 and 48 h with p value of (p = 0.002) and (p = 0.006) respectively. Oral Ivermectin was effective in treating nasal and nasopharyngeal myiasis, in terms of early clearance, decreased morbidity and less hospital stay. We conclude that oral Ivermectin can be used as a safe and effective method for the treatment of nasal & nasopharyngeal myiasis. © Association of Otolaryngologists of India 2018.

Entities:  

Keywords:  Ivermectin; Ivermectin in nasal myiasis; Nasal myiasis; Nasopharyngeal myiasis

Year:  2018        PMID: 31763286      PMCID: PMC6848309          DOI: 10.1007/s12070-018-1444-y

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  18 in total

Review 1.  Medicinal maggots: an ancient remedy for some contemporary afflictions.

Authors:  R A Sherman; M J Hall; S Thomas
Journal:  Annu Rev Entomol       Date:  2000       Impact factor: 19.686

2.  Myiasis by Chrysomya bezziana in surgical pathology.

Authors:  Philip C W Lui; May K P Lee; Joseph H C Wong; Chung-Ying Leung; Clary K L Lee; Raymond W M Lai; Edman T K Lam; Jane C C Yeung; Dacita T K Suen; Gary M K Tse
Journal:  Pathology       Date:  2005-02       Impact factor: 5.306

Review 3.  The chemistry and pharmacology of avermectins.

Authors:  M H Fisher; H Mrozik
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

4.  The specificity of high affinity binding of avermectin B1a to mammalian brain.

Authors:  S S Pong; C C Wang
Journal:  Neuropharmacology       Date:  1980-03       Impact factor: 5.250

5.  Characteristics of atrophic rhinitis in Thai patients at the Siriraj Hospital.

Authors:  C Bunnag; P Jareoncharsri; P Tansuriyawong; W Bhothisuwan; N Chantarakul
Journal:  Rhinology       Date:  1999-09       Impact factor: 3.681

6.  Endoscopy in nasal myiasis.

Authors:  N K Soni
Journal:  Trop Doct       Date:  2000-10       Impact factor: 0.731

7.  [Detection of progesterone receptors in connective tissue cells of the lower nasal turbinates in women].

Authors:  C Bowser; A Riederer
Journal:  Laryngorhinootologie       Date:  2001-04       Impact factor: 1.057

8.  The mechanism of action of avermectins in Caenorhabditis elegans: correlation between activation of glutamate-sensitive chloride current, membrane binding, and biological activity.

Authors:  J P Arena; K K Liu; P S Paress; E G Frazier; D F Cully; H Mrozik; J M Schaeffer
Journal:  J Parasitol       Date:  1995-04       Impact factor: 1.276

9.  Oral myiasis : case report.

Authors:  Roszalina Ramli; Roslan Abd Rahman
Journal:  Malays J Med Sci       Date:  2002-07

10.  Use of ivermectin in the treatment of orbital myiasis caused by Cochliomyia hominivorax.

Authors:  Paulo De Tarso; P Pierre-Filho; Nilza Minguini; Leandro M Pierre; Alessandra M Pierre
Journal:  Scand J Infect Dis       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.